EDGAR·FLOW

Armata Pharmaceuticals, Inc. — Form 8-K

Filed September 23, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War (through MTEC/NMRC) specifically for Phase 3 clinical development of AP-SA02, a bacteriophage therapeutic for complicated Staphylococcus aureus bacteremia. This is the first Phase 3-directed tranche under a broader DoW award; cumulative DoW funding for AP-SA02 now totals $32.4 million ($28.7M previously announced plus this $3.7M increment). The Phase 3 study is anticipated to initiate in H2 2026.
Why this rating

Non-dilutive capital of $3.7M is 17.5% of company market cap; cumulative $32.4M DoW award is 153% of market cap. Extends runway and validates lead program, critical for $21.1M-market-cap biotech. Positive but not transformational—execution risk remains.

Tradability signal
NO TRADE

No trade: the filing reads positive but the market is selling it (-7.7% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$4.45 ▲ 5.98%
at our read · unknown
$4.20
+10 min · unknown
$3.98 ▼ 5.36%
+30 min · unknown
$3.93 ▼ 6.43%
+1 hr · unknown
$3.77 ▼ 10.24%
+4 hrs · unknown
$3.68 ▼ 12.38%

The stock had already moved -5.64% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ARMP · stock on Yahoo Finance ↗

See more from September 23, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.